Logo image of KALA

KALA BIO INC (KALA) Stock Fundamental Analysis

NASDAQ:KALA - Nasdaq - US4831192020 - Common Stock - Currency: USD

6.64  -0.2 (-2.92%)

Fundamental Rating

1

KALA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of KALA have multiple concerns. KALA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KALA has reported negative net income.
KALA had a negative operating cash flow in the past year.
In the past 5 years KALA always reported negative net income.
KALA had a negative operating cash flow in each of the past 5 years.
KALA Yearly Net Income VS EBIT VS OCF VS FCFKALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

KALA's Return On Assets of -62.84% is on the low side compared to the rest of the industry. KALA is outperformed by 60.04% of its industry peers.
KALA's Return On Equity of -282.23% is on the low side compared to the rest of the industry. KALA is outperformed by 74.42% of its industry peers.
Industry RankSector Rank
ROA -62.84%
ROE -282.23%
ROIC N/A
ROA(3y)-76.45%
ROA(5y)-67.52%
ROE(3y)-549.04%
ROE(5y)-413.82%
ROIC(3y)N/A
ROIC(5y)N/A
KALA Yearly ROA, ROE, ROICKALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

KALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALA Yearly Profit, Operating, Gross MarginsKALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

KALA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KALA has more shares outstanding
Compared to 5 years ago, KALA has more shares outstanding
The debt/assets ratio for KALA is higher compared to a year ago.
KALA Yearly Shares OutstandingKALA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
KALA Yearly Total Debt VS Total AssetsKALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

KALA has an Altman-Z score of -15.65. This is a bad value and indicates that KALA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -15.65, KALA is not doing good in the industry: 83.30% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.66 is on the high side and indicates that KALA has dependencies on debt financing.
KALA's Debt to Equity ratio of 1.66 is on the low side compared to the rest of the industry. KALA is outperformed by 82.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Altman-Z -15.65
ROIC/WACCN/A
WACC10.86%
KALA Yearly LT Debt VS Equity VS FCFKALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 3.07 indicates that KALA has no problem at all paying its short term obligations.
KALA has a Current ratio of 3.07. This is in the lower half of the industry: KALA underperforms 64.30% of its industry peers.
KALA has a Quick Ratio of 3.07. This indicates that KALA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.07, KALA is not doing good in the industry: 62.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 3.07
KALA Yearly Current Assets VS Current LiabilitesKALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.18% over the past year.
The Revenue for KALA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)45.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.4%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KALA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.32% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.4%
EPS Next 2Y28.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALA Yearly Revenue VS EstimatesKALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
KALA Yearly EPS VS EstimatesKALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KALA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALA Price Earnings VS Forward Price EarningsKALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALA Per share dataKALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

KALA's earnings are expected to grow with 28.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KALA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALA BIO INC

NASDAQ:KALA (2/21/2025, 8:00:02 PM)

6.64

-0.2 (-2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners57.11%
Inst Owner Change-96.96%
Ins Owners2.35%
Ins Owner Change1.39%
Market Cap40.44M
Analysts85
Price Target15.3 (130.42%)
Short Float %2.82%
Short Ratio2.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.23%
Min EPS beat(2)-42.14%
Max EPS beat(2)29.67%
EPS beat(4)2
Avg EPS beat(4)-13.44%
Min EPS beat(4)-55.16%
Max EPS beat(4)29.67%
EPS beat(8)3
Avg EPS beat(8)-17.93%
EPS beat(12)5
Avg EPS beat(12)-18.9%
EPS beat(16)6
Avg EPS beat(16)-15.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.95
P/tB 2.95
EV/EBITDA N/A
EPS(TTM)-12.46
EYN/A
EPS(NY)-6.34
Fwd EYN/A
FCF(TTM)-5.1
FCFYN/A
OCF(TTM)-5.04
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.84%
ROE -282.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.45%
ROA(5y)-67.52%
ROE(3y)-549.04%
ROE(5y)-413.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 121.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 3.07
Altman-Z -15.65
F-Score2
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)116.52%
Cap/Depr(5y)144.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.4%
EPS Next Y38.4%
EPS Next 2Y28.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.33%
OCF growth 3YN/A
OCF growth 5YN/A